J&J's Janssen reports ibrutinib met primary endpoint of safety Janssen announced data from a study published in The Lancet Oncology, evaluating the safety and activity of ibrutinib as a single-agent therapy in patients over the age of 65 with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The study met its primary endpoint of safety, with data demonstrating treatment with ibrutinib as an initial therapy was associated with adverse events that were predominantly Grade 1 or 2 in nature. Efficacy data were also collected and showed that 71% of patients treated with ibrutinib achieved an objective response. Although estimates of progression-free survival and overall survival were not reached at the median follow up of 22.1 months, it is estimated that more than 95% of patients would be alive and progression-free at two years.
News For JNJ From The Last 14 Days
Check below for free stories on JNJ the last two weeks.